Screening for lung cancer
58 results
1 - 58Screening for lung cancer
Screening for lung cancer: Cochrane systematic review
Screening smokers for lung cancer with low-dose CT decreases lung cancer mortality
Consequences of screening for lung cancer (NELSON)
USPSTF recommends lung cancer screening for some smokers
Low‐dose computed tomography (LDCT) screening for lung cancer‐related mortality New
Uncertain risks and benefits of CT screening for lung cancer
CT screening for lung cancer: more cancers detected, no mortality benefit (DANTE)
Lower mortality with CT screening for lung cancer, but at very high cost
Annual screening chest x-ray does not reduce lung cancer mortality
Italian lung cancer screening findings consistent with US National Lung Screening Trial results (ITALUNG)
Low-dose CT screening of smokers decreases lung cancer deaths, but not overall mortality
Systematic review: lung cancer screening with CT decreases mortality but with significant harms
Lung cancer screening requires additional imaging in 40% of patients in real world
Lung cancer screening is cost effective, but only if done correctly
Spiral CT detects early lung cancer, but screening use is premature
USPSTF 2021 recommends annual lung cancer screening based on shared decision-making in high-risk adults (B recommendation)
Population screening for cancer
Low-dose CT screening decreases mortality in heavy smokers
High false-positive rate with lung cancer screening
Lung cancer screening with low-dose CT does not affect smoking cessation rates
Lung cancer screening may increase the likelihood of smoking cessation
Volume-based low-dose CT screening reduces lung cancer–specific mortality (NELSON)
One in five patients overdiagnosed with lung CA screening
Adherence to lung cancer screening is relatively poor after baseline scan
After community lung cancer screening, rates of follow-up imaging are lower but the rates of some procedures are higher
Lung cancer
Screening for ovarian cancer
High false positive rate in repeated, multimodal screening for cancers (PLCO)
CT finds early lung Ca but carries risk (PLuSS)
Prostate cancer screening: no mortality benefit after 13 years of follow-up (PLCO)
Probability of cancer in high-risk patients with pulmonary nodules detected by low-dose screening CT
PSA screening does not reduce mortality from prostate CA (PLCO)
Prostate cancer screening: no mortality benefit after 15 years of follow-up (PLCO)
Screening CA-125 and transvaginal ultrasound does not reduce ovarian cancer mortality
Need to screen 1055 and treat 37 to prevent one prostate CA death over 11 years (ERSPC)
Ovarian cancer screening does not improve outcomes (UKCTOCS)
Screening for ovarian cancer with CA-125/ultrasound algorithm does not reduce mortality (UKCTOCS)
Chemotherapy for non‐small cell lung cancer Stable (no update expected for reasons given in 'What's new')
PSA for screening of prostate cancer
PSA screening has marginal effect on mortality in European study (ERSPC)
Myositis
Impact of PSA screening on quality of life
Flex sig reduces incidence and mortality of colorectal cancer
Screening for prostate cancer New search for studies and content updated (no change to conclusions)
Systematic screening and assessment of psychosocial well‐being and care needs of people with cancer Edited (no change to conclusions)
Post-operative radiotherapy for ductal carcinoma in situ of the breast: Cochrane systematic review
Alcoholic liver disease (ALD)
Lymphomas
Clinical, functional, and demographic factors predict 10-year mortality in adults older than 50
Anti‐epidermal growth factor receptor therapy for glioblastoma in adults Edited (no change to conclusions)
Chemotherapy for advanced gastric cancer: Cochrane systematic review